KEGG   DRUG: OxaliplatinHelp
Entry
D01790                      Drug                                   

Name
Oxaliplatin (JAN/USAN/INN);
Eloxatin (TN)
Product
  Generic
OXALIPLATIN (Accord Healthcare), OXALIPLATIN (Actavis Pharma), OXALIPLATIN (Actavis Pharma), OXALIPLATIN (Alvogen), OXALIPLATIN (Apotex Corp.), OXALIPLATIN (Athenex Pharmaceutical Division), OXALIPLATIN (Baxter Healthcare Corporation), OXALIPLATIN (BluePoint Laboratories), OXALIPLATIN (Breckenridge Pharmaceutical), OXALIPLATIN (Breckenridge Pharmaceutical), OXALIPLATIN (Cipla USA), OXALIPLATIN (Fresenius Kabi USA), OXALIPLATIN (Gland Pharma Limited), OXALIPLATIN (Gland Pharma Limited), OXALIPLATIN (Hospira), OXALIPLATIN (Meitheal Pharmaceuticals), OXALIPLATIN (Mylan Institutional LLC), OXALIPLATIN (NorthStar RxLLC), OXALIPLATIN (Qilu Pharmaceutical), OXALIPLATIN (Sagent Pharmaceuticals), OXALIPLATIN (Sandoz), OXALIPLATIN (Sandoz), OXALIPLATIN (Sanja Pharmaceuticals Company), OXALIPLATIN (Sun Pharma Global FZE), OXALIPLATIN (Sun Pharma Global FZE), OXALIPLATIN (Winthrop U.S.), OXALIPLATIN (Winthrop U.S.)
Formula
Pt. C6H14N2. C2O4
Exact mass
397.0601
Mol weight
397.2918
Structure
Mol fileKCF fileDB search
Class
Antineoplastic
 DG01679  Platinum compound
Transporter substrate
 DG02858  SLC22A1 (OCT1) substrate
 DG02854  SLC22A2 (OCT2) substrate
Remark
Therapeutic category: 4291
ATC code: L01XA03
Product: D01790<JP/US>
Efficacy
Antineoplastic, Cell growth inhibitor
  Disease
Colorectal cancer [DS:H00020]
Comment
Platinum compound
DNA alkylator
Target
DNA
Metabolism
Transporter: SLC22A2 [HSA:6582], SLC22A1 [HSA:6580]
Interaction
Drug interaction
Structure map
map07040  Antineoplastics - alkylating agents
Other map
map01524  Platinum drug resistance
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XA Platinum compounds
     L01XA03 Oxaliplatin
      D01790  Oxaliplatin (JAN/USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D01790  Oxaliplatin (JAN/USAN/INN)
Antineoplastics [br08340.html]
 D01790
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D01790
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D01790
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D01790
BRITE hierarchy
Other DBs
CAS: 61825-94-3
PubChem: 7848852
ChEBI: 31941
DrugBank: DB00526
LigandBox: D01790
NIKKAJI: J2.108.891I
LinkDB All DBs
KCF data Show

ATOM        15
            1   O6a O    27.6304  -16.6769 #-
            2   C6a C    28.8402  -17.3773
            3   C6a C    30.0500  -16.6769
            4   O6a O    31.2599  -17.3773 #-
            5   O6a O    28.8402  -18.7782
            6   O6a O    30.0500  -15.2761
            7   C1x C    18.8079  -16.6698
            8   C1x C    18.8079  -18.0706
            9   C1x C    20.0240  -18.7710
            10  C1y C    21.2329  -18.0706
            11  C1y C    21.2329  -16.6698
            12  C1x C    20.0240  -15.9694
            13  N1a N    22.4327  -15.9781
            14  N1a N    22.4241  -18.7572
            15  Z   Pt   24.9608  -17.2359 #2+
BOND        13
            1     2   3 1
            2     3   4 1
            3     2   5 2
            4     1   2 1
            5     3   6 2
            6     7   8 1
            7     8   9 1
            8     9  10 1
            9    10  11 1
            10   11  12 1
            11   12   7 1
            12   11  13 1 #Up
            13   10  14 1 #Down

» Japanese version   » Back

DBGET integrated database retrieval system